A Multi-omics-based Metabolic Typing Study of Gastric Cancer

Gastric Cancer Clinical Trial

Official title:

Clinical Study on Metabolic Typing of Gastric Cancer Based on Transcriptome, Metabolome and Other Multi-omics

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT06134011
• Other study ID #: IRB-2023-935
• Status: Active, not recruiting
• Start date: September 10, 2023
• Est. completion date: September 10, 2024

Study information

• Verified date: November 2023
• Source: Zhejiang Cancer Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

In the study, the investigators obtained gastric cancer tissues from 480 gastric cancer patients who had undergone surgery at the Zhejiang Cancer Hospital's biospecimen bank between 2012-2019, and obtained relevant clinical information. The gastric cancer tissues were subjected to transcriptomic, metabolomic and other multi-omics testing, and analyzed for the metabolic changes of gastric cancer, and proposed to discover relevant therapeutic targets.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 480
• Est. completion date: September 10, 2024
• Est. primary completion date: September 10, 2024
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• 18=age=80

• Histologically or cytologically confirmed gastric cancer

• Undergo surgery for radical or palliative gastric cancer (both open and laparoscopic)

• Patients with survival follow-up information

Exclusion Criteria:

• Two or more kinds of malignant tumors at the same time

• Incomplete or missing case information

• Preoperative diagnosis of residual gastric cancer

Related Conditions & MeSH terms

• Diagnosis
• Gastric Cancer
• Stomach Neoplasms

Intervention

Other:
• Without any intervention
There were no special interventions for the two groups.

Locations

Country	Name	City	State
China	Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)	Hangzhou	Zhejiang

Sponsors (1)

Lead Sponsor	Collaborator
Zhejiang Cancer Hospital

Country where clinical trial is conducted

China, 

References & Publications (3)

Li S, Yuan L, Xu ZY, Xu JL, Chen GP, Guan X, Pan GZ, Hu C, Dong J, Du YA, Yang LT, Ni MW, Jiang RB, Zhu X, Lv H, Xu HD, Zhang SJ, Qin JJ, Cheng XD. Integrative proteomic characterization of adenocarcinoma of esophagogastric junction. Nat Commun. 2023 Feb — View Citation

Shi W, Wang Y, Xu C, Li Y, Ge S, Bai B, Zhang K, Wang Y, Zheng N, Wang J, Wang S, Ji G, Li J, Nie Y, Liang W, Wu X, Cui J, Wang Y, Chen L, Zhao Q, Shen L, He F, Qin J, Ding C. Multilevel proteomic analyses reveal molecular diversity between diffuse-type a — View Citation

Wang J, Kunzke T, Prade VM, Shen J, Buck A, Feuchtinger A, Haffner I, Luber B, Liu DHW, Langer R, Lordick F, Sun N, Walch A. Spatial Metabolomics Identifies Distinct Tumor-Specific Subtypes in Gastric Cancer Patients. Clin Cancer Res. 2022 Jul 1;28(13):28 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The differences of the metabolism information	The differences of the metabolism information between gastric cancer tissues and non-cancerous gastric cancer tissues. These data included Metabolizing enzyme mRNA expression and metabolite content.	through study completion, an average of 6 months